- Stocks
- Pharma & Healthcare
- Dr. Lal Path Labs
Dr. Lal Path Labs share price
NSE: LALPATHLABPharma & HealthcareDiagnostics & Research
Dr. Lal Path Labs at a glance
Dr. Lal Path Labs (NSE: LALPATHLAB) closed at ₹1,838.50 on 22 Oct 2026, up 0.46% on the day. With a market capitalisation of ₹30,820 Cr, it ranks 265th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
At its last close the stock traded at 58× trailing earnings, against a return on equity of 20.1% in FY26. Over the past year the share price has risen 16.3%. Its 52-week range is ₹1,272.60 (23 Mar 2026) to ₹2,038.60 (16 Sep 2026); the last close is 9.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹798 Cr (+19.1% year on year) and net profit ₹171 Cr (+27.2%), on a consolidated basis. Promoters held 53.19% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹30,820 CrRank 265 on NSE
- P/E (trailing)
- 58×
- Price to book
- 8.78×FY26
- EPS (TTM)
- ₹41.48to Q1 FY27
- ROE
- 20.1%FY26
- ROCE
- 26.8%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 18.4%FY26
- Book value / share
- ₹149.69FY26
- Dividend payout
- 43.0%FY26
- 52-week high
- ₹2,038.6016 Sep 2026
- 52-week low
- ₹1,272.6023 Mar 2026
- 1-year return
- +16.3%
- RSI (14-day)
- 39.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.46% | −4.8% | −3.7% | +8.2% | +16.3% |
Dr. Lal Path Labs quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹660 Cr | ₹597 Cr | ₹603 Cr | ₹670 Cr | ₹731 Cr | ₹660 Cr | ₹703 Cr | ₹798 Cr |
| Revenue YoY | +9.8% | +10.7% | +10.5% | +11.3% | +10.7% | +10.6% | +16.6% | +19.1% |
| Net profit | ₹131 Cr | ₹98 Cr | ₹156 Cr | ₹134 Cr | ₹152 Cr | ₹91 Cr | ₹132 Cr | ₹171 Cr |
| Net profit YoY | +18.2% | +19.3% | +81.2% | +24.3% | +16.4% | −6.8% | −15.0% | +27.2% |
| Net margin | 19.8% | 16.4% | 25.8% | 20.0% | 20.8% | 13.9% | 18.8% | 21.4% |
| EPS | ₹15.52 | ₹11.60 | ₹18.57 | ₹15.88 | ₹18.05 | ₹5.42 | ₹7.86 | ₹10.15 |
Dr. Lal Path Labs financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,581 Cr | ₹2,087 Cr | ₹2,017 Cr | ₹2,227 Cr | ₹2,461 Cr | — |
| Operating profit | ₹394 Cr | ₹475 Cr | ₹344 Cr | ₹505 Cr | ₹625 Cr | — |
| Net profit | ₹296 Cr | ₹350 Cr | ₹241 Cr | ₹362 Cr | ₹492 Cr | — |
| EPS (₹) | ₹35.00 | ₹42.00 | ₹29.00 | ₹43.00 | ₹58.00 | — |
| Cash from operations | ₹398 Cr | ₹447 Cr | ₹456 Cr | ₹535 Cr | ₹569 Cr | — |
| Total debt | ₹0 Cr | ₹167 Cr | ₹83 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹1,245 Cr | ₹1,508 Cr | ₹1,666 Cr | ₹1,849 Cr | ₹2,173 Cr | ₹2,508 Cr |
Dr. Lal Path Labs shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 22 Dec 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 53.79% | 53.21% | 53.21% | 53.21% | 53.21% | 53.19% |
| Foreign institutions | 21.68% | 21.86% | 20.68% | 20.29% | 17.18% | 17.36% |
| Domestic institutions | 17.91% | 18.49% | 18.96% | 19.21% | 21.38% | 21.59% |
| Non-institutions | 6.23% | 6.07% | 6.79% | 6.94% | 7.87% | 7.47% |
Dr. Lal Path Labs vs peers
The listed Pharma & Healthcare companies nearest to Dr. Lal Path Labs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| NHNarayana Hrudayalaya | ₹1,691.90 | −2.21% | −2.8% | ₹34,576 Cr | 42.4 | — |
| EMCUREEmcure Pharmaceuticals | ₹1,759.20 | +0.09% | +31.6% | ₹33,369 Cr | 145.1 | — |
| MEDANTAGlobal Health | ₹1,215.10 | −1.65% | −10.1% | ₹32,671 Cr | 58.9 | — |
| LALPATHLABDr. Lal Path Labs | ₹1,838.50 | +0.46% | +16.3% | ₹30,820 Cr | 58 | — |
| WOCKPHARMAWockhardt | ₹1,889.60 | +0.46% | +38.2% | ₹30,705 Cr | 144.8 | — |
| SAILIFESai Life Sciences | ₹1,396.80 | −0.06% | +63.2% | ₹29,652 Cr | 85.1 | — |
| KIMSKrishna Institute of Medical Sciences | ₹671.30 | +0.04% | −5.5% | ₹28,195 Cr | 111.9 | — |
Ask anything about Dr. Lal Path Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against LALPATHLAB's own history. Try: “Why has LALPATHLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on LALPATHLAB over five years” · “Compare LALPATHLAB with NH on margins and valuation”
Frequently asked questions about Dr. Lal Path Labs
What is the share price of Dr. Lal Path Labs today?
Dr. Lal Path Labs (NSE: LALPATHLAB) last closed at ₹1,838.50 on 22 Oct 2026. Its 52-week high is ₹2,038.60 and its 52-week low is ₹1,272.60.
What is the market cap of Dr. Lal Path Labs?
Dr. Lal Path Labs' market capitalisation is ₹30,820 Cr (₹30,820 Cr) at the 22 Oct 2026 close, ranking 265th among the NSE companies Pivot tracks.
What is the P/E ratio of Dr. Lal Path Labs?
Dr. Lal Path Labs trades at a trailing P/E of 58. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 111.9.
What is the ROE and ROCE of Dr. Lal Path Labs?
Return on equity was 20.1% in FY26 and return on capital employed was 26.8% in FY26 (consolidated figures).
Is Dr. Lal Path Labs a debt-free company?
Dr. Lal Path Labs is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Dr. Lal Path Labs' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Dr. Lal Path Labs reported revenue of ₹798 Cr, +19.1% year on year, and net profit of ₹171 Cr, +27.2% year on year.
How has Dr. Lal Path Labs stock performed over the last year?
Dr. Lal Path Labs' share price has risen 16.3% over the past year, +8.2% over three months and −3.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Dr. Lal Path Labs?
As of 30 Jun 2026: promoters 53.19%, foreign institutions 17.36%, domestic institutions 21.59%, non-institutions 7.47%.
Who are Dr. Lal Path Labs' competitors?
The listed Pharma & Healthcare companies closest to Dr. Lal Path Labs by market cap are Narayana Hrudayalaya, Emcure Pharmaceuticals, Global Health, Wockhardt, Sai Life Sciences and Krishna Institute of Medical Sciences.
Is Dr. Lal Path Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Dr. Lal Path Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LALPATHLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with D · all NSE stocks · this page as text